The STEP trials revealed over the previous 12 months have established the efficacy and security of semaglutide in treating sufferers with weight problems. A brand new research analysing the consequences of this remedy in several age teams introduced at this 12 months’s European Congress on Weight problems (held on-line, 10-13 Could), reveals that it has comparable effectiveness throughout totally different age teams with regard to weight reduction (underneath 40 years, 40-60 years, and 60 years and over).
Nevertheless when share body fats and lean body mass modifications, semaglutide was discovered to to have a extra pronounced impact in sufferers aged underneath 50 years. The research is by Dr. Dror Dicker, Hasharon Hospital-Rabin Medical Heart and Tel Aviv College, Tel Aviv, Israel, and colleagues.
Semaglutide, which belongs to the category of medicine referred to as glucagon-like peptide-1 (GLP-1) receptor agonists, was initially developed for and can also be used to deal with kind 2 diabetes. Nevertheless, its results on weight loss led researchers to review its impact on weight reduction in folks residing with weight problems however with out kind 2 diabetes. It’s at present not accredited for weight problems anyplace on the earth, nevertheless new drug functions are underneath evaluate by the US Meals and Drug Administration (FDA), the European Medicines Company (EMA), and different well being companies internationally.
Weight reduction is usually accompanied by lack of lean physique mass, which may negatively affect bodily functioning and/or resting power expenditure. Physique weight reduction and physique composition modifications (fats mass vs lean mass) might differ by age. Thus on this research of information from the STEP 1 trial (see hyperlink to unique research beneath), the authors evaluated the tolerability and impact of subcutaneous semaglutide 2.4 mg on weight reduction and physique composition in response to age.
Adults with out kind 2 diabetes with physique mass index (BMI) of 27 kg/m² or over (chubby) with a minimum of one weight-related comorbidity, or a BMI of 30 kg/m² or above (with weight problems) have been enrolled. Topics have been randomised to a once-weekly injection of semaglutide 2.4 mg or placebo, each plus life-style intervention, for 68 weeks. Change in physique weight (%) from randomisation to week 68 was analysed in response to age: underneath 40 years (n=655), over 40 to underneath 60 years (n=981),and 60 years and over (n=325). Security and tolerability have been additionally re-analysed throughout these teams.
Complete physique fats mass and complete lean physique mass have been measured utilizing twin power X-ray absorptiometry (DEXA) scans in a randomly chosen subgroup of 140 adults (who then gave consent) with BMI of 40 kg/m² or underneath at baseline and week 68. Physique composition (share physique fats mass, share lean physique mass, lean:fats mass ratio) have been analysed in response to age lower than 50 and 50 years or older.
In STEP 1, most topics have been feminine (74%); imply age was 46 years, imply physique weight was 105 kg, and imply BMI was 38 kg/m². Change in physique weight (%) was better for semaglutide than for placebo and was constant throughout age teams: 40 years and underneath imply weight reduction 15.2% semaglutide group versus 2.3% placebo; 40-60 years 14.6kg semaglutide versus 2.5kg placebo; and 60 years and over 14.7kg semaglutide versus 2.4kg placebo. The modifications in lean:fats mass ratio have been discovered to be extra pronounced in these sufferers underneath 50 years—the authors recommend the metabolic results of ageing may very well be behind this distinction.
The protection of semaglutide was typically constant throughout age teams. Gastrointestinal issues have been essentially the most generally reported adversarial occasions throughout all age teams.
The authors conclude: “On this new evaluation of the STEP 1 trial, weight reduction with once-weekly semaglutide 2.4 mg was achieved constantly throughout totally different age teams. There was no proof of variations in remedy impact by weight loss and physique composition throughout age teams for semaglutide or placebo. Remedy with semaglutide decreased share physique fats mass and elevated share lean physique mass in all topics, which was extra pronounced in these aged underneath 50 years. Semaglutide was typically nicely tolerated with an adversarial occasion profile according to the identified class results of this drug—glucagon-like peptide-1 receptor agonists (GLP-1) – regardless of age.”
European Affiliation for the Examine of Weight problems
Examine reveals new weight problems remedy semaglutide causes comparable weight reduction throughout totally different age teams (2021, Could 13)
retrieved 13 Could 2021
This doc is topic to copyright. Other than any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for data functions solely.